Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine

Jill K. Badin, Victor Progar, Anisha Pareddy, Jordan Cagle, Mouhamad Alloosh, Michael Sturek

Research output: Contribution to journalArticle

Abstract

According to a single study in dogs that was conducted in 1949, the diabetic effects of the β-cell toxin alloxan are dependent on age. The current study examined whether this age-dependence of alloxan is present in the clinically relevant Ossabaw miniature swine (Sus scrofa domestica) model of metabolic syndrome. Juvenile swine (n = 8; age, 4.3 ± 0.2 mo) and adult swine (n = 8; age, 7.4 ± 0.2 mo) received alloxan (average dosage, 140 mg/kg IV) and were placed on a hypercaloric, atherogenic diet for 6 mo. The metabolic syndrome profile was confirmed by measuring body weight, cholesterol, and triglycerides. Intravenous glucose tolerance testing was used to assess glucose clearance and peripheral plasma insulin levels. The β-cell mass was calculated by immunohistochemical staining of pancreatic tissue. Although juvenile and adult swine exhibited comparable severity of metabolic syndrome, adult swine developed impaired glucose clearance and elevated fasting blood glucose levels at 6 mo after alloxan administration on the atherogenic diet. Peripheral plasma insulin levels in juvenile and adult swine were comparable at all time points and lower than in nonalloxan-treated age-matched controls, which is reflected in the lower pancreatic β-cell mass of the 2 treated groups. However, compared with adult pigs, juvenile swine exhibited greater insulin response recovery (complete or partial restoration of peripheral insulin levels to reference values) at 6 mo after alloxan administration. Overall, these results indicate that youth can confer some protection against the diabetogenic effects of alloxan in swine, potentially due in part to the greater insulin response recovery of young pigs. This study supports previous research that the effects of alloxan are dependent on the developmental maturity of the animal.

Original languageEnglish (US)
Pages (from-to)114-122
Number of pages9
JournalComparative medicine
Volume69
Issue number2
DOIs
StatePublished - Apr 1 2019

Fingerprint

Miniature Swine
alloxan
miniature swine
Alloxan
Swine
swine
Insulin
insulin
metabolic syndrome
Atherogenic Diet
Nutrition
Glucose
Plasmas
Recovery
Sus scrofa
Metabolome
Restoration
high energy diet
Blood Glucose
glycemic effect

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • veterinary(all)

Cite this

Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine. / Badin, Jill K.; Progar, Victor; Pareddy, Anisha; Cagle, Jordan; Alloosh, Mouhamad; Sturek, Michael.

In: Comparative medicine, Vol. 69, No. 2, 01.04.2019, p. 114-122.

Research output: Contribution to journalArticle

Badin, Jill K. ; Progar, Victor ; Pareddy, Anisha ; Cagle, Jordan ; Alloosh, Mouhamad ; Sturek, Michael. / Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine. In: Comparative medicine. 2019 ; Vol. 69, No. 2. pp. 114-122.
@article{22d2b023388649da88eafae2e54f4a2b,
title = "Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine",
abstract = "According to a single study in dogs that was conducted in 1949, the diabetic effects of the β-cell toxin alloxan are dependent on age. The current study examined whether this age-dependence of alloxan is present in the clinically relevant Ossabaw miniature swine (Sus scrofa domestica) model of metabolic syndrome. Juvenile swine (n = 8; age, 4.3 ± 0.2 mo) and adult swine (n = 8; age, 7.4 ± 0.2 mo) received alloxan (average dosage, 140 mg/kg IV) and were placed on a hypercaloric, atherogenic diet for 6 mo. The metabolic syndrome profile was confirmed by measuring body weight, cholesterol, and triglycerides. Intravenous glucose tolerance testing was used to assess glucose clearance and peripheral plasma insulin levels. The β-cell mass was calculated by immunohistochemical staining of pancreatic tissue. Although juvenile and adult swine exhibited comparable severity of metabolic syndrome, adult swine developed impaired glucose clearance and elevated fasting blood glucose levels at 6 mo after alloxan administration on the atherogenic diet. Peripheral plasma insulin levels in juvenile and adult swine were comparable at all time points and lower than in nonalloxan-treated age-matched controls, which is reflected in the lower pancreatic β-cell mass of the 2 treated groups. However, compared with adult pigs, juvenile swine exhibited greater insulin response recovery (complete or partial restoration of peripheral insulin levels to reference values) at 6 mo after alloxan administration. Overall, these results indicate that youth can confer some protection against the diabetogenic effects of alloxan in swine, potentially due in part to the greater insulin response recovery of young pigs. This study supports previous research that the effects of alloxan are dependent on the developmental maturity of the animal.",
author = "Badin, {Jill K.} and Victor Progar and Anisha Pareddy and Jordan Cagle and Mouhamad Alloosh and Michael Sturek",
year = "2019",
month = "4",
day = "1",
doi = "10.30802/AALAS-CM-18-000037",
language = "English (US)",
volume = "69",
pages = "114--122",
journal = "Comparative Medicine",
issn = "1532-0820",
publisher = "American Association for Laboratory Animal Science",
number = "2",

}

TY - JOUR

T1 - Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine

AU - Badin, Jill K.

AU - Progar, Victor

AU - Pareddy, Anisha

AU - Cagle, Jordan

AU - Alloosh, Mouhamad

AU - Sturek, Michael

PY - 2019/4/1

Y1 - 2019/4/1

N2 - According to a single study in dogs that was conducted in 1949, the diabetic effects of the β-cell toxin alloxan are dependent on age. The current study examined whether this age-dependence of alloxan is present in the clinically relevant Ossabaw miniature swine (Sus scrofa domestica) model of metabolic syndrome. Juvenile swine (n = 8; age, 4.3 ± 0.2 mo) and adult swine (n = 8; age, 7.4 ± 0.2 mo) received alloxan (average dosage, 140 mg/kg IV) and were placed on a hypercaloric, atherogenic diet for 6 mo. The metabolic syndrome profile was confirmed by measuring body weight, cholesterol, and triglycerides. Intravenous glucose tolerance testing was used to assess glucose clearance and peripheral plasma insulin levels. The β-cell mass was calculated by immunohistochemical staining of pancreatic tissue. Although juvenile and adult swine exhibited comparable severity of metabolic syndrome, adult swine developed impaired glucose clearance and elevated fasting blood glucose levels at 6 mo after alloxan administration on the atherogenic diet. Peripheral plasma insulin levels in juvenile and adult swine were comparable at all time points and lower than in nonalloxan-treated age-matched controls, which is reflected in the lower pancreatic β-cell mass of the 2 treated groups. However, compared with adult pigs, juvenile swine exhibited greater insulin response recovery (complete or partial restoration of peripheral insulin levels to reference values) at 6 mo after alloxan administration. Overall, these results indicate that youth can confer some protection against the diabetogenic effects of alloxan in swine, potentially due in part to the greater insulin response recovery of young pigs. This study supports previous research that the effects of alloxan are dependent on the developmental maturity of the animal.

AB - According to a single study in dogs that was conducted in 1949, the diabetic effects of the β-cell toxin alloxan are dependent on age. The current study examined whether this age-dependence of alloxan is present in the clinically relevant Ossabaw miniature swine (Sus scrofa domestica) model of metabolic syndrome. Juvenile swine (n = 8; age, 4.3 ± 0.2 mo) and adult swine (n = 8; age, 7.4 ± 0.2 mo) received alloxan (average dosage, 140 mg/kg IV) and were placed on a hypercaloric, atherogenic diet for 6 mo. The metabolic syndrome profile was confirmed by measuring body weight, cholesterol, and triglycerides. Intravenous glucose tolerance testing was used to assess glucose clearance and peripheral plasma insulin levels. The β-cell mass was calculated by immunohistochemical staining of pancreatic tissue. Although juvenile and adult swine exhibited comparable severity of metabolic syndrome, adult swine developed impaired glucose clearance and elevated fasting blood glucose levels at 6 mo after alloxan administration on the atherogenic diet. Peripheral plasma insulin levels in juvenile and adult swine were comparable at all time points and lower than in nonalloxan-treated age-matched controls, which is reflected in the lower pancreatic β-cell mass of the 2 treated groups. However, compared with adult pigs, juvenile swine exhibited greater insulin response recovery (complete or partial restoration of peripheral insulin levels to reference values) at 6 mo after alloxan administration. Overall, these results indicate that youth can confer some protection against the diabetogenic effects of alloxan in swine, potentially due in part to the greater insulin response recovery of young pigs. This study supports previous research that the effects of alloxan are dependent on the developmental maturity of the animal.

UR - http://www.scopus.com/inward/record.url?scp=85064726313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064726313&partnerID=8YFLogxK

U2 - 10.30802/AALAS-CM-18-000037

DO - 10.30802/AALAS-CM-18-000037

M3 - Article

C2 - 30894246

AN - SCOPUS:85064726313

VL - 69

SP - 114

EP - 122

JO - Comparative Medicine

JF - Comparative Medicine

SN - 1532-0820

IS - 2

ER -